PsyTech

A number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: ATAI) last week. Ratings ranged from a sober sector performance rating from RBC Capital Markets with a $19 12-month price target to a bullish Overweight rating from Cantor Fitzgerald,...

On Tuesday, Wesana Health Holdings (CSE: WESA), a life science company that champions the development of psychedelics and other medicines for the treatment of traumatic brain injury, announced a definitive agreement to acquire PsyTech Inc. in an all-stock transaction for approximately CA$21...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Cannabis Co. Pharmadrug Signs LOI To Purchase Dutch Psychedelics Retailer Super Smart...

The use of psychedelic drugs to treat a host of mental health problems ranging from depression and anxiety, to addiction and PTSD, is gaining new favor in the scientific community. Similar to how attitudes about cannabis have pivoted in recent years, people are now rethinking of how...